Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 28, Issue 11, Pages 818-830Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2017.09.001
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81500647, 81471039, 81270893]
- Natural Science Foundation Project of Chongqing [CSTC2014jcyjjq10006, CSTC2016jcyjA0502]
- National Key R&D Program of China [2016YFC1101100, 2017YFC1309600]
- Young Doctor Diabetic Research Fund of International Medical Communication
Ask authors/readers for more resources
p62, a protein capable of binding both ubiquitin and autophagy substrates, is well established as a key regulator in cancer and neurodegenerative diseases. Recently, there has been accumulating evidence that p62 is also a pivotal regulator in metabolic diseases, such as obesity, T2DM, NAFLD, metabolic bone disease, gout and thyroid disease. This review summarizes the emerging role of p62 on these diseases by considering its functional domains, phenotypes in genetically modified animals, clinically observed alterations, and its effects on downstream metabolic signaling pathways. At the same time, we highlight the need to explore the roles played by p62 in the gastrointestinal environment and immune system, and the extent to which its elevated expression may confer protection against metabolic disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available